Amgen (AMGN) : Cumberland Partners Ltd added new position in Amgen during the most recent quarter end. The investment management firm now holds 1,847 shares of Amgen which is valued at $315,246 , the company said in a statement filed on Jul 26, 2016 with the SEC.Amgen makes up approximately 0.04% of Cumberland Partners Ltd’s portfolio.
Other Hedge Funds, Including , Aviance Capital Management boosted its stake in AMGN in the latest quarter, The investment management firm added 858 additional shares and now holds a total of 8,581 shares of Amgen which is valued at $1,464,605. Amgen makes up approx 0.04% of Aviance Capital Management’s portfolio.Atwood Palmer Inc reduced its stake in AMGN by selling 200 shares or 1.43% in the most recent quarter. The Hedge Fund company now holds 13,781 shares of AMGN which is valued at $2,283,098. Amgen makes up approx 0.40% of Atwood Palmer Inc’s portfolio.F&v Capital Management reduced its stake in AMGN by selling 455 shares or 1.04% in the most recent quarter. The Hedge Fund company now holds 43,410 shares of AMGN which is valued at $6,993,351. Amgen makes up approx 5.10% of F&v Capital Management’s portfolio.Raymond James Trust N.a. boosted its stake in AMGN in the latest quarter, The investment management firm added 8,185 additional shares and now holds a total of 36,838 shares of Amgen which is valued at $5,934,602. Amgen makes up approx 0.50% of Raymond James Trust N.a.’s portfolio.Next Financial Group Inc boosted its stake in AMGN in the latest quarter, The investment management firm added 15 additional shares and now holds a total of 2,118 shares of Amgen which is valued at $341,210. Amgen makes up approx 0.11% of Next Financial Group Inc’s portfolio.
Amgen opened for trading at $171.57 and hit $172.26 on the upside on Friday, eventually ending the session at $172.03, with a gain of 0.44% or 0.75 points. The heightened volatility saw the trading volume jump to 31,21,594 shares. Company has a market cap of $129,232 M.
On the company’s financial health, Amgen reported $2.84 EPS for the quarter, beating the analyst consensus estimate by $ 0.10 according to the earnings call on Jul 27, 2016. Analyst had a consensus of $2.74. The company had revenue of $5688.00 million for the quarter, compared to analysts expectations of $5579.33 million. The company’s revenue was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.57 EPS.
Investors should note that on Jul 22, 2016, Amgen announced a cash dividend of $1.0000. The company’s management has announced Aug 15, 2016 as the ex-dividend date and fixed the record date on Aug 17, 2016. The payable date has been fixed on Sep 8, 2016.
Many Wall Street Analysts have commented on Amgen. Amgen was Initiated by Bernstein to “Mkt Perform” on Jun 29, 2016.
Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.